Our top pick for
Beginners

Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Braze, which develops a platform between consumers and brands, completed its initial public offering, selling 8 million shares at $65 each, above its $55 to $60 price range.
BRZE trades on the Nasdaq.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Active traders
Latest market close | $43.35 |
---|---|
52-week range | $27.09 - $98.78 |
50-day moving average | $35.47 |
200-day moving average | $49.10 |
Wall St. target price | $49.80 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-1.94 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $43.35 from 2022-07-05
1 week (2022-06-29) | 22.18% |
---|---|
1 month (2022-06-07) | 15.66% |
3 months (2022-04-07) | 14.11% |
6 months (2022-01-07) | -32.28% |
1 year (2021-07-03) | N/A |
---|---|
2 years (2020-07-03) | N/A |
3 years (2019-07-03) | N/A |
5 years (2017-07-03) | N/A |
Revenue TTM | $267.7 million |
---|---|
Gross profit TTM | $159.5 million |
Return on assets TTM | -11.67% |
Return on equity TTM | -37.68% |
Profit margin | -38.54% |
Book value | $5.17 |
Market capitalisation | $3.7 billion |
TTM: trailing 12 months
We're not expecting Braze to pay a dividend over the next 12 months.
Braze, Inc. operates a customer engagement platform that provides interactions between consumers and brands worldwide. It offers data ingestion products, such as Braze software development kits that automatically manage data ingestion and the delivery of mobile and web notifications, in-application/in-browser interstitial messages, and content cards, as well as can be integrated into a range of digital interfaces and application development frameworks; REST API that can be used to import or export data or to trigger workflows between Braze and brands' existing technology stacks; and partner cohort syncing, which allow brands to sync user cohorts from partners. The company also offers classification products, including segmentation that can define reusable segments of consumers based upon attributes, events, or predictive propensity scores; segment insights, which allows customers to analyze how segments are performing relative to each other across a set of pre-selected key performance indicators, and helps to understand the factors that determine which consumers belong to a particular segment; and predictive suite that allows customers to identify groups of consumers that are of critical business value. In addition, it provides personalization and action products; and orchestration products, which include Canvas, an orchestration tool that allows customers to create journeys, mapping out multi-steps, and cross-channel messaging experiences, which include onboarding flows, nurture campaigns, win-back strategies, and others; campaigns, which allow customers to send one set of single-channel or multi-channel messages to be delivered to customers in a particular user segment; event and API triggering; frequency capping and rate limiting; intelligent selection; and reporting and analytics. The company was formerly known as Appboy, Inc. and changed its name to Braze, Inc.
Everything we know about the Citrine Global IPO, plus information on how to buy in.
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.